LP
INDV icon

LMR Partners’s Indivior Pharmaceuticals INDV Stock Holding History

LMR Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-88,783
Closed -$846K – 1504
2025
Q1 		$846K Buy
+88,783
New +$933K 0.01% 817
2024
Q3 		– Sell
-10,489
Closed -$169K – 1395
2024
Q2 		$169K Hold
10,489
– – ﹤0.01% 866
2024
Q1 		$225K Buy
+10,489
New +$197K ﹤0.01% 851

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LMR Partners's INDV Position: Q2 2025 in Review

LMR Partners sold out of Indivior Pharmaceuticals (INDV) in Q2 2025, closing a stake of 88,783 shares — an estimated $846K sold.

LMR Partners first reported a position in INDV in Q1 2024 and held it in 3 quarters. The position peaked at $846K in Q1 2025. 120 funds tracked by Wall St. Rank hold INDV as of Q2 2025.

  • LMR Partners reported no remaining Indivior Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • LMR Partners sold 88,783 Indivior Pharmaceuticals shares in Q2 2025, an estimated $846K.
  • LMR Partners first reported a position in Indivior Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • LMR Partners's Indivior Pharmaceuticals position peaked at $846K in Q1 2025.
  • 120 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.